We grow tumors in the laboratory that mimic tumors found in a patient’s body. Good laboratory tumor models lead to clinical success.
TumorGenesis is a global developer of world-class and innovative technologies using 3-dimensional cell culture and media. We specialize in discovering and developing technologies that preserve the patients’ derived cancer tissue biological signatures, thus allowing researchers to study cancer in the laboratory using cancer samples that mimic the tumors found in the patients. Better cancer models lead to successful clinical outcomes and faster drug approvals, benefiting the pharma and biotech companies and the cancer patients awaiting better treatment.
We address cancer discovery and development problems.
Predictive Oncology’s business units bring a wide array of assets across the Drug Discovery Spectrum helping to eliminate cancer at every step in the process, from discovery to approval.
Predictive Oncology’s team can solve:
We have systems that grow cancer cells better, faster, and retain their patient derived signatures.
We grow patient-derived tumors that a pathologist would see as a sample that looks like the original biopsy.
Because we retain 95%+ of the patient’s cancer biomarkers, our drug screening results are more reliable and predictive of clinical success.
We discover and develop media, matrices, and biomarkers that are tailored to cancer’s variety of cells found in a tumor colony. Finding drugs and drug combinations that kill all the cancer cells is the key to clinical and drug approval success.
Personalized medicine: select the right drug for the patient’s cancer.
Predictive Oncology brought to the market for ovarian cancer patients over 10 years ago the first clinically relevant test that informed oncologists and patients the response rate to the Standard of Care treatment for ovarian cancer, Taxol and Cis (or Carbo) platin treatment. A positive response in our 2-D assay translated to a survival from 39 months to over 85 months.